Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody
MW33 的安全性、耐受性、药代动力学特征和免疫原性:针对 SARS-CoV-2 RBD 的单克隆抗体的 1 期临床研究
期刊:Emerging Microbes & Infections
影响因子:8.4
doi:10.1080/22221751.2021.1960900
Xianmin Meng, Peipei Wang, Yanqing Xiong, Yijun Wu, Xiaoyan Lin, Song Lu, Ruowan Li, Bei Zhao, Jing Liu, Shaoqing Zeng, Liyan Zeng, Yan Wu, Yan Lu, Jinchao Zhang, Datao Liu, Shuhai Wang, Hongzhou Lu